Certara, Inc. announced that Jon Resnick will become its next chief executive officer, effective January 1, 2026. Resnick brings more than 20 years of experience in the life‑sciences technology sector, most recently serving as President of the United States and Canada region for IQVIA. His background in data analytics and commercial growth is expected to accelerate Certara’s Model‑Informed Drug Development platform and expand its AI‑enabled biosimulation capabilities.
The appointment follows Certara’s recent launch of Certara IQ, an AI‑powered Quantitative Systems Pharmacology platform unveiled in October 2025. Resnick’s expertise in large‑scale analytics and market expansion aligns with the company’s strategy to monetize the new platform and broaden its customer base across biopharmaceuticals, academia, and regulatory agencies. The board highlighted that Resnick’s track record at IQVIA—where he drove significant revenue growth and operational scaling—positions him to lead the next phase of growth for Certara’s software‑and‑services mix.
William F. Feehery will step down as CEO on December 31, 2025, and will transition to an external advisory role during the handover period. Feehery’s continued presence on the board is intended to provide continuity and preserve institutional knowledge as the company moves into a new leadership era.
Financially, Certara reaffirmed its full‑year 2025 outlook, projecting revenue of $415 million to $420 million and an adjusted EBITDA margin of approximately 32%. In the third quarter, the company reported earnings per share of $0.11, slightly exceeding the consensus estimate of $0.1099, and revenue of $104.6 million, marginally above the expected $104.64 million. The modest beat reflects disciplined cost management and a favorable mix of high‑margin software contracts, offsetting a slight decline in legacy services revenue.
Management emphasized the strategic importance of the transition. Chairman James E. Cashman III said, “We are excited to welcome Jon to Certara. He brings a proven track record of building and scaling market leaders, advancing technological innovation in healthcare and life sciences, and fostering collaborative teams. We are confident that his leadership will help propel Certara to its next phase of growth and realize the full potential of model‑informed drug development.” Resnick added, “I am thrilled to join Certara, a market‑leading company at the forefront of innovation in drug discovery.” CFO John Gallagher noted that the company’s Q3 results “show strong demand for biosimulation solutions in software and QSP services, while we are raising our 2025 profitability targets and narrowing our revenue guidance to reflect the most likely range.”
The transition is expected to reinforce Certara’s focus on AI‑driven biosimulation, support the commercialization of Certara IQ, and sustain the company’s high‑margin software and services mix. With Resnick’s data‑analytics expertise and Feehery’s advisory continuity, Certara aims to maintain its momentum in a competitive life‑sciences technology market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.